Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine

References

• Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, [Internet] 2013. [cited 2016 Aug 28]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/index.html.
   Google Scholar
• Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol. 2003;24:690–698.
   PubMed Web of Science ®Google Scholar
• Ford CD, Lopansri BK, Haydoura S, et al. Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect. Control Hosp Epidemiol. 2015;36:47–53.
   PubMed Web of Science ®Google Scholar
• Worth LJ, Thursky KA, Seymour JF, et al. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol. 2007;79:226–233.
   PubMed Web of Science ®Google Scholar
• Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis. 1996;23:1234–1239.
   PubMed Web of Science ®Google Scholar
• Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994;38:1363–1367.
   PubMed Web of Science ®Google Scholar
• Mazuski JE. Vancomycin-resistant enterococcus: risk factors, surveillance, infections, and treatment. Surg Infect (Larchmt). 2008;9:567–571.
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Lesse AJ, Hahn T, et al. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2011;32:490–496.
   PubMed Web of Science ®Google Scholar
• Timmers GJ, van der Zwet WC, Simoons-Smit IM, et al. Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: Risk factor assessment and successful control of the epidemic. Br J Haematol. 2002;116:826–833.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–431.
   PubMed Web of Science ®Google Scholar
• Padiglione AA, Wolfe R, Grabsch EA, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother. 2003;4:2492–2498.
   Web of Science ®Google Scholar
• Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med. 1999;159:2461–2468.
   PubMed Web of Science ®Google Scholar
• Calderwood MS, Mauer A, Tolentino J, et al. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol. 2008;29:1019–1025.
   PubMed Web of Science ®Google Scholar
• Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010;19:231–237.
   PubMed Web of Science ®Google Scholar
• Suppola JP, Volin L, Valtonen VV, et al. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis. 1996;23:694–697.
   PubMed Web of Science ®Google Scholar
• Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103–1111.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Frencken JF, Tarima S, et al. Handling time-dependent variables: antibiotics and antibiotic resistance. Clin Infect Dis. 2016;62:1558–1563.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Zaas AK, Song X, Tucker P, et al. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2002;35:1139–1146.
   PubMed Web of Science ®Google Scholar
• Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993;16:750–755.
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. Pharmacokinetics of vancomycin. J Antimicrob Chemother. 1984;14:43–52.
   PubMed Web of Science ®Google Scholar
• Currie BP, Lemos-Filho L. Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2004;48:4427–4429.
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.
   PubMedGoogle Scholar
• van Prehn J, Stemerding AM, Van Saene HK, et al. Oral vancomycin might be useful to suppress enteral VRE load: a conceptual experiment. Intensive Care Med. 2014;40:1171–1172.
   PubMed Web of Science ®Google Scholar
• Donskey CJ, Hanrahan JA, Hutton RA, et al. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis. 1999;180:384–390.
   PubMed Web of Science ®Google Scholar
• Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother. 2008;52:2403–2406.
   PubMed Web of Science ®Google Scholar
• Miller M, Bernard L, Thompson M, et al. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol. 2010;31:710–715.
   PubMed Web of Science ®Google Scholar
• Salgado CD, Giannetta ET, Farr BM. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile. Infect Control Hosp Epidemiol. 2004;25:413–417.
   PubMed Web of Science ®Google Scholar
• Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47:471–505.
   PubMed Web of Science ®Google Scholar
• Richards DM, Heel RC, Brogden RN, et al. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984;27:469–527.
   PubMed Web of Science ®Google Scholar
• Okamoto MP, Gill MA, Nakahiro RK, et al. Tissue concentrations of cefepime in acute cholecystitis patients. Ther Drug Monit. 1992;14:220–225.
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Kastanakis M, Markogiannakis A, et al. Pharmacokinetics of cefepime in bile and gall bladder tissue after prophylactic administration in patients with extrahepatic biliary diseases. Int J Antimicrob Agents. 2006;27:331–334.
   PubMed Web of Science ®Google Scholar
• Kato N, Bando K, Muto Y, et al. Effect of parenteral cefepime on human fecal flora. Chemother. 1991;39:52–58.
   Google Scholar
• Bächer K, Schaeffer M, Lode H, et al. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother. 1992;30:365–375.
   PubMed Web of Science ®Google Scholar